Jones E, Callen J P
Department of Medicine, University of Louisville, KY.
J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):487-9. doi: 10.1016/0190-9622(90)70246-e.
Cutaneous sarcoidosis often responds poorly to topical and intralesional corticosteroids but may respond to moderate to high doses of oral corticosteroids. To avoid the use of systemic corticosteroids, we treated 17 patients with cutaneous sarcoidal granulomas with hydroxychloroquine (2 to 3 mg/kg/day) in an open clinical trial. If response occurred, other medications were first tapered and then the hydroxychloroquine dosage was reduced or stopped. The cutaneous lesions of 12 patients regressed within 4 to 12 weeks, and they were able to stop other therapies; three patients had a partial response, and two patients had no regression. Two of eight patients with pulmonary sarcoidosis improved. No ocular toxicity was noted.
皮肤结节病通常对局部和病灶内注射皮质类固醇反应不佳，但可能对中至大剂量口服皮质类固醇有反应。为避免使用全身性皮质类固醇，我们在一项开放性临床试验中用羟氯喹（2至3毫克/千克/天）治疗了17例皮肤结节性肉芽肿患者。如果有反应，先逐渐减少其他药物用量，然后降低或停用羟氯喹剂量。12例患者的皮肤病变在4至12周内消退，他们能够停用其他疗法；3例患者有部分反应，2例患者病变未消退。8例肺部结节病患者中有2例病情改善。未观察到眼部毒性。
